PHARMA REMAINS IN THE DOLDRUMS.

The article discusses the declining sales and earnings of several pharmaceutical firms due to patent losses. It informs that company sales of Sanofi SA were increased by 3.3 percent and was benefited by the diabetes area and the Genzyme biopharmaceuticals unit of its growth market which makes up to 70 percent of its sales. Also presented is a table related to the sales of firms.